

# Vladimir V Rafalski

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/3594564/vladimir-v-rafalski-publications-by-citations.pdf>

**Version:** 2024-04-19

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

61  
papers

15,548  
citations

35  
h-index

70  
g-index

70  
ext. papers

19,761  
ext. citations

15.7  
avg, IF

6.2  
L-index

#	Paper	IF	Citations
61	Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes. <i>New England Journal of Medicine</i> , <b>2017</b> , 377, 644-657	59.2	3789
60	Angiotensin-neprilysin inhibition versus enalapril in heart failure. <i>New England Journal of Medicine</i> , <b>2014</b> , 371, 993-1004	59.2	3301
59	Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome. <i>New England Journal of Medicine</i> , <b>2015</b> , 373, 2247-57	59.2	1393
58	A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. <i>New England Journal of Medicine</i> , <b>2006</b> , 354, 1001-10	59.2	1146
57	Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. <i>New England Journal of Medicine</i> , <b>2006</b> , 354, 1011-20	59.2	948
56	Angiotensin-Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction. <i>New England Journal of Medicine</i> , <b>2019</b> , 381, 1609-1620	59.2	705
55	Angiotensin receptor neprilysin inhibition compared with enalapril on the risk of clinical progression in surviving patients with heart failure. <i>Circulation</i> , <b>2015</b> , 131, 54-61	16.7	430
54	Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naïve patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): a phase 3, randomised, double-blind, placebo-controlled trial. <i>Lancet, The</i> , <b>2014</b> , 384, 403-13	40	394
53	Dual angiotensin receptor and neprilysin inhibition as an alternative to angiotensin-converting enzyme inhibition in patients with chronic systolic heart failure: rationale for and design of the Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure trial (PARADIGM-HF). <i>European Journal of Heart Failure</i> , <b>2013</b> , 15, 1002-7	12.3	264
52	Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease. <i>New England Journal of Medicine</i> , <b>2021</b> , 384, 129-139	59.2	243
51	Vedolizumab versus Adalimumab for Moderate-to-Severe Ulcerative Colitis. <i>New England Journal of Medicine</i> , <b>2019</b> , 381, 1215-1226	59.2	240
50	Once-daily simeprevir (TMC435) with pegylated interferon and ribavirin in treatment-naïve genotype 1 hepatitis C: the randomized PILLAR study. <i>Hepatology</i> , <b>2013</b> , 58, 1918-29	11.2	233
49	Eltrombopag before procedures in patients with cirrhosis and thrombocytopenia. <i>New England Journal of Medicine</i> , <b>2012</b> , 367, 716-24	59.2	230
48	Risk Related to Pre-Diabetes Mellitus and Diabetes Mellitus in Heart Failure With Reduced Ejection Fraction: Insights From Prospective Comparison of ARNI With ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure Trial. <i>Circulation: Heart Failure</i> , <b>2016</b> , 9,	7.6	201
47	Efficacy and safety of canagliflozin, an inhibitor of sodium-glucose cotransporter 2, when used in conjunction with insulin therapy in patients with type 2 diabetes. <i>Diabetes Care</i> , <b>2015</b> , 38, 403-11	14.6	171
46	Cardiac Myosin Activation with Omecamtiv Mecarbil in Systolic Heart Failure. <i>New England Journal of Medicine</i> , <b>2021</b> , 384, 105-116	59.2	164
45	Efficacy and safety of LCZ696 (sacubitril-valsartan) according to age: insights from PARADIGM-HF. <i>European Heart Journal</i> , <b>2015</b> , 36, 2576-84	9.5	129

44	Baseline characteristics and treatment of patients in prospective comparison of ARNI with ACEI to determine impact on global mortality and morbidity in heart failure trial (PARADIGM-HF). <i>European Journal of Heart Failure</i> , <b>2014</b> , 16, 817-25	12.3	119
43	Rationale, design and baseline characteristics of the CANagliflozin cardioVascular Assessment Study-Renal (CANVAS-R): A randomized, placebo-controlled trial. <i>Diabetes, Obesity and Metabolism</i> , <b>2017</b> , 19, 387-393	6.7	101
42	Importance of Clinical Worsening of Heart Failure Treated in the Outpatient Setting: Evidence From the Prospective Comparison of ARNI With ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure Trial (PARADIGM-HF). <i>Circulation</i> , <b>2016</b> , 133, 2254-62	16.7	96
41	Comparing LCZ696 with enalapril according to baseline risk using the MAGGIC and EMPHASIS-HF risk scores: an analysis of mortality and morbidity in PARADIGM-HF. <i>Journal of the American College of Cardiology</i> , <b>2015</b> , 66, 2059-2071	15.1	87
40	Influence of Sacubitril/Valsartan (LCZ696) on 30-Day Readmission After Heart Failure Hospitalization. <i>Journal of the American College of Cardiology</i> , <b>2016</b> , 68, 241-248	15.1	81
39	Influenza Vaccination in Patients With Chronic Heart Failure: The PARADIGM-HF Trial. <i>JACC: Heart Failure</i> , <b>2016</b> , 4, 152-158	7.9	73
38	Ferric carboxymaltose prevents recurrence of anemia in patients with inflammatory bowel disease. <i>Clinical Gastroenterology and Hepatology</i> , <b>2013</b> , 11, 269-77	6.9	72
37	Rationale, design, and baseline characteristics in Evaluation of LIXisenatide in Acute Coronary Syndrome, a long-term cardiovascular end point trial of lixisenatide versus placebo. <i>American Heart Journal</i> , <b>2015</b> , 169, 631-638.e7	4.9	72
36	Estimating the Long-Term Treatment Benefits of Sacubitril-Valsartan. <i>New England Journal of Medicine</i> , <b>2015</b> , 373, 2289-90	59.2	71
35	1425 SIMEPREVIR (TMC435) WITH PEGINTERFERON/RIBAVIRIN FOR CHRONIC HCV GENOTYPE-1 INFECTION IN TREATMENT-NAÏVE PATIENTS: RESULTS FROM QUEST-1, A PHASE III TRIAL. <i>Journal of Hepatology</i> , <b>2013</b> , 58, S574	13.4	68
34	Dementia-related adverse events in PARADIGM-HF and other trials in heart failure with reduced ejection fraction. <i>European Journal of Heart Failure</i> , <b>2017</b> , 19, 129-137	12.3	68
33	A putative placebo analysis of the effects of LCZ696 on clinical outcomes in heart failure. <i>European Heart Journal</i> , <b>2015</b> , 36, 434-9	9.5	66
32	Type of Atrial Fibrillation and Outcomes in Patients With Heart Failure and Reduced Ejection Fraction. <i>Journal of the American College of Cardiology</i> , <b>2017</b> , 70, 2490-2500	15.1	65
31	Efficacy and safety of canagliflozin when used in conjunction with incretin-mimetic therapy in patients with type 2 diabetes. <i>Diabetes, Obesity and Metabolism</i> , <b>2016</b> , 18, 82-91	6.7	65
30	Randomized trial of peginterferon alfa-2b and ribavirin for 48 or 72 weeks in patients with hepatitis C virus genotype 1 and slow virologic response. <i>Hepatology</i> , <b>2010</b> , 52, 1201-7	11.2	57
29	Effects of Sacubitril/Valsartan in the PARADIGM-HF Trial (Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure) According to Background Therapy. <i>Circulation: Heart Failure</i> , <b>2016</b> , 9,	7.6	53
28	Income Inequality and Outcomes in Heart Failure: A Global Between-Country Analysis. <i>JACC: Heart Failure</i> , <b>2019</b> , 7, 336-346	7.9	42
27	Prognostic Value of N-Terminal Pro-B-Type Natriuretic Peptide Levels in Heart Failure Patients With and Without Atrial Fibrillation. <i>Circulation: Heart Failure</i> , <b>2017</b> , 10,	7.6	37

26	Growth differentiation factor-15 is not modified by sacubitril/valsartan and is an independent marker of risk in patients with heart failure and reduced ejection fraction: the PARADIGM-HF trial. <i>European Journal of Heart Failure</i> , <b>2018</b> , 20, 1701-1709	12.3	34
25	Sharing Data from Cardiovascular Clinical Trials--A Proposal. <i>New England Journal of Medicine</i> , <b>2016</b> , 375, 407-9	59.2	33
24	The effects of sacubitril/valsartan on coronary outcomes in PARADIGM-HF. <i>American Heart Journal</i> , <b>2017</b> , 188, 35-41	4.9	24
23	Omecamtiv mecarbil in chronic heart failure with reduced ejection fraction: GALACTIC-HF baseline characteristics and comparison with contemporary clinical trials. <i>European Journal of Heart Failure</i> , <b>2020</b> , 22, 2160-2171	12.3	24
22	Efficacy and safety of Ergoferon versus oseltamivir in adult outpatients with seasonal influenza virus infection: a multicenter, open-label, randomized trial. <i>International Journal of Infectious Diseases</i> , <b>2016</b> , 51, 47-55	10.5	22
21	Quinolones for uncomplicated acute cystitis in women. <i>The Cochrane Library</i> , <b>2006</b> , CD003597	5.2	21
20	Assessing routine healthcare pattern for type 2 diabetes mellitus in Russia: the results of Barmacoepidemiological study (FORSIGHT-DM2). <i>Diabetes Mellitus</i> , <b>2016</b> , 19, 443-456	1.6	21
19	Sacubitril/valsartan reduces serum uric acid concentration, an independent predictor of adverse outcomes in PARADIGM-HF. <i>European Journal of Heart Failure</i> , <b>2018</b> , 20, 514-522	12.3	20
18	Antimicrobial susceptibility of pathogens isolated from adult patients with uncomplicated community-acquired urinary tract infections in the Russian Federation: two multicentre studies, UTIAP-1 and UTIAP-2. <i>International Journal of Antimicrobial Agents</i> , <b>2006</b> , 28 Suppl 1, S4-9	14.3	18
17	Cost-of-Illness Analysis of Type 2 Diabetes Mellitus in the Russian Federation: Results from Russian multicenter observational pharmacoepidemiologic study of diabetes care for patients with type 2 diabetes mellitus (FORSIGHT-DM). <i>Diabetes Mellitus</i> , <b>2017</b> , 20, 403-419	1.6	13
16	Surface-enhanced Raman spectroscopy for antiplatelet therapy effectiveness assessment. <i>Laser Physics Letters</i> , <b>2020</b> , 17, 045601	1.5	12
15	Distribution and antibiotic resistance profile of key Gram-negative bacteria that cause community-onset urinary tract infections in the Russian Federation: RESOURCE multicentre surveillance 2017 study. <i>Journal of Global Antimicrobial Resistance</i> , <b>2020</b> , 21, 188-194	3.4	8
14	Dataset of human platelets in healthy and individuals with cardiovascular pathology obtained by surface-enhanced Raman spectroscopy. <i>Data in Brief</i> , <b>2020</b> , 29, 105145	1.2	4
13	Prospects for Raman spectroscopy in cardiology. <i>Cardiovascular Therapy and Prevention (Russian Federation)</i> , <b>2020</b> , 19, 70-77	0.9	3
12	EPIDEMIOLOGY OF UNCOMPLICATED OUTPATIENT URINARY TRACT INFECTIONS IN THE RUSSIAN FEDERATION. <i>Urology Herald</i> , <b>2018</b> , 6, 30-37	0.4	3
11	Sa2072 Simeprevir (TMC435) With Peginterferon/Ribavirin for Chronic HCV Genotype-1 Infection in Treatment-Naïve Patients: Results From QUEST-1, a Phase III Trial. <i>Gastroenterology</i> , <b>2013</b> , 144, S-374 <sup>13-3</sup>		2
10	LOW DOSAGE ACETYLSALICYLIC ACID: A VARIETY OF FORMULATIONS. <i>Cardiovascular Therapy and Prevention (Russian Federation)</i> , <b>2017</b> , 16, 68-75	0.9	2
9	Antibiotic resistance of pathogens causing uncomplicated urinary tract infections in Russian Federation. <i>Urology Herald</i> , <b>2018</b> , 6, 50-56	0.4	2

8	NMR spectroscopy reveals acetylsalicylic acid metabolites in the human urine for drug compliance monitoring. <i>PLoS ONE</i> , <b>2021</b> , 16, e0247102	3.7	2
7	Quinolones for uncomplicated acute cystitis in women <b>2002</b> ,		1
6	Single human platelet study using surface-enhanced Raman spectroscopy as a perspective tool for antiplatelet therapy effectiveness prediction <b>2019</b> ,		1
5	Spectral homogeneity of human platelets investigated by SERS.. <i>PLoS ONE</i> , <b>2022</b> , 17, e0265247	3.7	1
4	Prospects for Raman spectroscopy in cardiology. <i>Cardiovascular Therapy and Prevention (Russian Federation)</i> ,19, 70-77	0.9	0
3	Use of secondary prevention drug therapy in patients with acute coronary syndrome after hospital discharge in Russian practice. <i>European Heart Journal</i> , <b>2013</b> , 34, P2514-P2514	9.5	
2	Spectral and time-resolved photoluminescence of human platelets doped with platinum nanoparticles. <i>PLoS ONE</i> , <b>2021</b> , 16, e0256621	3.7	
1	The results of phase III multicenter open randomized controlled study REM-Chol-III-16 in patients with intrahepatic cholestasis syndrome caused by chronic diffuse liver diseases. <i>Terapevticheskii Arkhiv</i> , <b>2021</b> , 93, 1470-1476	0.9	